Zobrazeno 1 - 10
of 26
pro vyhledávání: '"D E, Yocum"'
Publikováno v:
Biochemical and Biophysical Research Communications. 297:890-897
Parathyroid hormone-related protein (PTHrP), a multifunctional peptide that acts as a vasodilator as well as possible regulator of vascular development, is produced in increased amounts in the rheumatoid synovium. To understand whether PTHrP can cont
Autor:
D E, Yocum
Publikováno v:
Springer Seminars in Immunopathology. 23:63-72
It is clear that the rate of infection is increased in most of the more serious forms of autoimmune disease and agents such as high-dose steroids and the alkylating agents increase this risk. Other agents such as MTX, CsA, LEF, AZA and the TNF antago
Autor:
D E Yocum
Publikováno v:
Rheumatology. 37:1145-1147
Publikováno v:
Cellular and molecular biology (Noisy-le-Grand, France). 49(2)
Autoantibodies directed against variable domain epitopes of the alpha/beta T cell receptor (TCR) occur in sera of man, mouse and other vertebrates. Here, we focus upon autoantibodies expressed in human rheumatoid arthritis (RA) and systemic erythemat
Autor:
E W, St Clair, S B, Cohen, M L, Lee, R M, Fleischmann, S H, Lee, L W, Moreland, N J, Olsen, P W, Pratt, D E, Yocum, L, Heck, J, Winkelhake, J S, Holcenberg, M J, Shulman
Publikováno v:
The Journal of rheumatology. 27(8)
To determine the safety and potential clinical efficacy of primary and booster injections of a DR4/1 peptide in patients with active rheumatoid arthritis (RA) despite methotrexate therapy. METHODS. Subjects with active RA were enrolled in a randomize
Autor:
D E, Yocum, S, Allard, S B, Cohen, P, Emery, R M, Flipo, J, Goobar, S, Jayawardena, C, Job-Deslandre, R W, Jubb, K, Krüger, A, Lopes Vaz, B, Manger, E, Mur, H, Nygaard, S M, Weiner, F, Rainer, M R, Sack, M H, Schiff, T J, Schnitzer, L B, Trigg, I, Whatmough, A G, Schmidt
Publikováno v:
Rheumatology (Oxford, England). 39(2)
To compare the safety, tolerability and efficacy of the new oral microemulsion formulation of cyclosporin A (CyA; Sandimmun Neoral) and the original CyA formulation (Sandimmun), in patients with severe active rheumatoid arthritis (RA), over a 12-mont
Autor:
D E, Yocum, A M, Solinger, J, Tesser, O, Gluck, M, Cornett, F, O'Sullivan, K, Nordensson, B, Dallaire, C D, Shen, J, Lipani
Publikováno v:
The Journal of rheumatology. 25(7)
The goal of this single infusion, dose escalation study was to evaluate the safety of the PRIMATIZED anti-CD4 monoclonal antibody (Mab), IDEC-CE9.1, in patients with rheumatoid arthritis (RA).Twenty-five patients received single infusions of IDEC-CE9
Proinflammatory cytokines, including tumor necrosis factor (TNF) and interleukin 1 (IL-1), mediate the joint destruction that characterizes rheumatoid arthritis (RA). Previous studies have shown that parathyroid hormone-related protein (PTHrP) is a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::563ccb697d006f4694a60eb3c2382a23
https://europepmc.org/articles/PMC508713/
https://europepmc.org/articles/PMC508713/
Autor:
T J, Schnitzer, D E, Yocum, M, Michalska, R, Balius, M E, Snider, A, Hays, L M, Thurmond, J M, Johnston
Publikováno v:
The Journal of rheumatology. 24(6)
A 24 week study of subcutaneous (sq) dosing with titration of CAMPATH-1H (C1H) dose against the circulating CD4+ T cell count in patients with rheumatoid arthritis (RA) was undertaken to examine the safety, biologic activity, and clinical efficacy of
Autor:
D E, Yocum
Publikováno v:
The Journal of rheumatology. Supplement. 44
The role of combination therapy in rheumatoid arthritis is increasing with the recent development of various new treatment modalities. While past combinations of slow acting antirheumatic drugs have resulted in either excessive side effects or lack o